Board Recommends All Anavex 2-73 Trials Proceed

Board Recommends All Anavex 2-73 Trials Proceed

291854

Board Recommends All Anavex 2-73 Trials Proceed

An independent monitoring board has recommended that all three ongoing clinical trials of Anavex 2-73 (blarcamesine), an investigational treatment for Rett syndrome, continue without changes, based on a review of interim safety data. Anavex Life Sciences, the medication’s developer, announced the decision in a press release. Data Safety Monitoring Boards are used in clinical studies to protect the interests of the participants and the integrity of the data. All three trials — AVATAR (NCT03941444), EXCELLENCE (NCT04304482), and a…

You must be logged in to read/download the full post.